Trial intelligence / Profile preview

Pyrotinib for HER2-positive breast cancer with brain metastases (real-world study)

ChiCTR2000037995Phase 4Recruiting

Sponsor
Shandong Cancer Hospital
Start
Sep 2020
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of pyrotinib in breast cancer and brain metastases, sponsored by Shandong Cancer Hospital. Primary endpoints: Progression Free Survival and Adverse Events. Started Sep 2020; status: recruiting.

02

Drugs

pyrotinib
03

Conditions

breast cancerbrain metastases

Beyond the preview

Go deeper on ChiCTR2000037995.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2000037995.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call